Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagno...(to marketable products or services;Roset...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
Date:6/11/2008
to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Contact:
Media
Rachel Spielman,
T: +1-212-583-2714,
Investors
Ron Kamienchick,
T: +1-646-509-1893,
E: investors@rosettagenomics.com
'/>"/>
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. /C O R R E C T I O N -- Rosetta Genomics Ltd/
2. Rosetta Genomics Reports First Quarter 2008 Financial Results
3. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
4. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
5. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
6. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
7. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
8. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
9. Rosetta Genomics Establishes Medical Advisory Board
10. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
11. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
Post Your Comments:
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3
[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening[0] Vivakor Confirms Record Date of Stock Dividend
Other Biology Technology:LifeNet Health Chief Scientific Officer Wins Award 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 3BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 4BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 5BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 6BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 7BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 8
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Zix Corporation Addresses New HIPAA Regulations 49867 1Zix Corporation Addresses New HIPAA Regulations 49867 2Zix Corporation Addresses New HIPAA Regulations 49867 3Report 3A Primary Care Doctors in Greatest Demand 49865 1Report 3A Primary Care Doctors in Greatest Demand 49865 2Fertility Information Will Enhance Reproductive Health Awareness 49863 1
Other Biology News:The brain's executive is an 'event planner' 2Finding paves way for better treatment of autoimmune disease 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |